Affiliation: Stanford University
- Antiangiogenesis agents in the treatment of soft tissue sarcomasKristen Ganjoo
Division of Oncology, Stanford University, Palo Alto, CA, USA
Cancer 116:1177-83. 2010..In addition, the authors conducted an in-depth review of the results from using key antiangiogenesis agents in the treatment of STS...
- Current and emerging pharmacological treatments for gastrointestinal stromal tumourKristen N Ganjoo
Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, Stanford, California, USA
Drugs 71:321-30. 2011..The duration of adjuvant therapy is currently under evaluation; however, it is possible that these patients would need to continue therapy indefinitely...
- New developments in targeted therapy for soft tissue sarcomaKristen N Ganjoo
Stanford University, 269 Campus Drive, Stanford, CA 94305, USA
Curr Oncol Rep 12:261-5. 2010....
- A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcomaKristen N Ganjoo
Stanford University Medical Center, Stanford, Calif, USA
Oncology 80:50-6. 2011..Patients and..
- Trabectedin: an anticancer drug from the seaKristen N Ganjoo
Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Expert Opin Pharmacother 10:2735-43. 2009..Trabectedin (ET-743) is an anticancer agent originally isolated from Ecteinascidia turbinata, a marine organism...
- The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patientsKristen N Ganjoo
Division of Oncology, Stanford University, Stanford, CA, USA
J Cancer Res Clin Oncol 134:381-7. 2008..This is a single institution retrospective study evaluating the role of angiogenesis markers in the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL)...
- Non-Hodgkin lymphoma of the breastKristen Ganjoo
Department of Medical Oncology, Stanford University, Stanford, California, USA
Cancer 110:25-30. 2007..A retrospective study was done to evaluate the institutional experience in this patient population...
- Antiangiogenesis: a new approach to the treatment of lymphomaKristen Ganjoo
Department of Medicine (Oncology, Stanford University, Palo Alto, CA 94304, USA
Leuk Lymphoma 48:454-5. 2007
- Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysisKristen N Ganjoo
Department of Medicine Oncology, Stanford University, CA, USA
Leuk Lymphoma 47:998-1005. 2006..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
- Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancerJonathan W Riess
Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
Cancer Invest 30:231-5. 2012..268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients...
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter StudyBrad S Kahl
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Cancer 116:106-14. 2010..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...
- A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancerChristelle Clément-Duchêne
Division of Oncology, Department of Medicine, Department of Biostatistics, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
J Thorac Oncol 5:1821-5. 2010..This study was designed to evaluate toxicities and efficacy of gemcitabine/carboplatin/bevacizumab...
- Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth FactorRondeep Brar
Department of Internal Medicine, Stanford University Medical Center, Stanford, Calif, USA
Case Rep Oncol 2:242-250. 2009..CONCLUSION: Angiosarcoma of the breast is an aggressive malignancy with a propensity for both local recurrence and distant metastases. Angiogenesis inhibition may represent a novel therapeutic modality in this rare, vascular malignancy...
- Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndromeEve Henry
Department of Medicine, Stanford University, Stanford, California, USA
J Natl Compr Canc Netw 10:939-42. 2012....
- 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphomaAndrei Iagaru
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Mol Imaging Biol 12:198-203. 2010..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
- Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemiaArthur E Frankel
Department of Medicine, Scott and White Hospital, Temple, Texas 76508, USA
Cancer 106:2158-64. 2006....